Loading...
Loading...
Also known as: Fragment 177-191, hGH fragment
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Benefits
6
Conditions
5
Evidence
Strong preclinical evidence, limited human efficacy data+ studies
Source
Synthetic hGH fragment (amino acids 177-191)
Gabriel Brain Score
Moderate
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Binds beta-3 adrenergic receptors on adipocytes, increases cAMP/PKA signaling, activates hormone-sensitive lipase for lipolysis, inhibits lipogenic enzymes, no GH receptor binding (no IGF-1 elevation), preferentially accumulates in adipose tissue.
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Strong preclinical evidence, limited human efficacy data
Excellent safety profile in human trials. Animal studies show significant fat loss. Human trials have not consistently demonstrated weight loss despite good safety. Mechanisms well-characterized in preclinical models.
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.
Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.
Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.